This content is in French.
Hepatoblastoma: a combined strategy to target resistant forms
27 mars 2026
By Elodie Vaz | Published on March 27, 2026 | 4 min readHepatoblastoma is the most common liver cancer in children. Although standard treatment combining chemotherapy and surgery now cures about 80% of patients, some forms remain particularly aggressive. These tumors are characterized by rapid proliferation and resistance to conventional therapies, leaving clinicians with limited options for poor-
By Elodie Vaz | Published on March 27, 2026 | 4 min read
Hepatoblastoma is the most common liver cancer in children. Although standard treatment combining chemotherapy and surgery now cures about 80% of patients, some forms remain particularly aggressive. These tumors are characterized by rapid proliferation and resistance to conventional therapies, leaving clinicians with limited options for poor-prognosis cases.
In this context, a team from Inserm and the University of Bordeaux, led by Christophe Grosset at the Bordeaux Institute of Oncology, has explored a new therapeutic strategy published in Springer Nature on February 26. The objective: eliminate resistant tumor cells by combining an EZH2 inhibitor (a protein involved in epigenetic regulation) with statins, drugs commonly prescribed for hypercholesterolemia.
Hepatoblastoma is the most common liver cancer in children. Although standard treatment combining chemotherapy and surgery now cures about 80% of patients, some forms remain particularly aggressive. These tumors are characterized by rapid proliferation and resistance to conventional therapies, leaving clinicians with limited options for poor-prognosis cases.
In this context, a team from Inserm and the University of Bordeaux, led by Christophe Grosset at the Bordeaux Institute of Oncology, has explored a new therapeutic strategy published in Springer Nature on February 26. The objective: eliminate resistant tumor cells by combining an EZH2 inhibitor (a protein involved in epigenetic regulation) with statins, drugs commonly prescribed for hypercholesterolemia.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Grosset C, et al. EZH2 is a key prognostic marker and therapeutic target in aggressive and proliferative hepatoblastoma. Molecular Cancer. 2025; doi:10.1186/s12943-025-02474-9.
View the source
